1. Home
  2. XENE vs TLX Comparison

XENE vs TLX Comparison

Compare XENE & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XENE

Xenon Pharmaceuticals Inc.

HOLD

Current Price

$40.38

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

HOLD

Current Price

$7.00

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XENE
TLX
Founded
1996
2015
Country
Canada
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.3B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
XENE
TLX
Price
$40.38
$7.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
4
Target Price
$54.09
$21.00
AVG Volume (30 Days)
954.8K
165.3K
Earning Date
02-26-2026
01-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.04
Revenue
$7,500,000.00
$664,225,558.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$167.21
Revenue Growth
N/A
55.35
52 Week Low
$26.74
$6.98
52 Week High
$46.60
$30.36

Technical Indicators

Market Signals
Indicator
XENE
TLX
Relative Strength Index (RSI) 41.76 36.78
Support Level $40.43 $7.16
Resistance Level $43.70 $8.45
Average True Range (ATR) 1.58 0.25
MACD -0.04 -0.03
Stochastic Oscillator 23.81 5.06

Price Performance

Historical Comparison
XENE
TLX

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: